S25\u2005The impact of COVID-19 on the UK severe asthma population

Abstract

S25 Table 1Characteristics of severe asthma patients with suspected or confirmed mild (ambulatory) or severe (hospitalised) COVID-19 infection Mild COVID-19 (n=84)Hospitalised with COVID-19 (n=13)p-valueAge (Years) (mean [SD])50 5 (13 8)55 6 (13 7)0 215Male Gender (n [%])39 (46 4%)4 (30 8%)0 290BMI (kg-m2) (mean [SD])31 3 (6 3)31 3 (4 9)0 967Non-Caucasian Ethnicity (n [%])15 (17 9%)3 (25 0%)0 553Atopic Disease (n [%])48 (62 3%)10 (76 9%)0 310FEV1% Predicted (mean [SD])67 9 (59 9,82 8)73 7 (60 1,84 8)0 555ICS Dose (BDP equivalent-ug) (median [IQR])2000 (1600,2000)1000 (800,1600)0 002On Maintenance OCS (n [%])35 (47 9%)3 (23 1%)0 872Evidence of Poor Adherence (n [%])18 (24 7%)7 (53 8%)0 033Maintenance Macrolides (n [%])7 (9 9%)2 (16 7%)0 428On Asthma Biologic (n [%])57 (67 9%)8 (61 5%)0 652Shielding against COVID-19Followed Shielding Advice (n [%])64 (84 2%)9 (90 0%)0 631Shielding affected mental health (n [%])33 (46 5%)5 (50 0%)0 835Contracted COVID-19 Before Shielding (n [%])40 (60 6%)4 (40 0%)0 219ConclusionHospitalisation and death occurred in small numbers in our severe asthma population From this observational data, biologic agents for asthma were not associated with increased risk of COVID-19 infection or hospitalisation